The Cambridge IBS Study
This double-blind, placebo-controlled study examines the role of probiotic administration in the prevention of C. difficile-associated diarrhoea (CDAD) in elderly patients receiving antibiotic therapy.
Results showed that Lab4 probiotics reduced the incidence of Clostridium difficile diarrhoea in these patients.
46% of patients supplemented with Lab4 probiotics were positive for Clostridium difficile toxin compared to 78% of patients in the placebo group
Caecal Biopsy and Caecal Lumen
- Group 2 – detection of yeasts was reduced at day 14 compared with Group 1.
- Group 1 – the percentage of IBS sufferers harbouring yeasts at day 28 (14 days after terminating antibiotic treatment) was higher than at day 0.
- Group 2 – yeasts were not detected in the faecal samples at day 28.